Back to top

Analyst Reiterates Buy on CTI with Unchanged $5 Price Target, Citing CTIM-76 Differentiation and Strategic Focus on CT-202

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Context Therapeutics, with a price target of $5.00. Emily ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Context Therapeutics Inc. (CNTX)